Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at SVB Leerink

Research analysts at SVB Leerink began coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note issued on Tuesday, Briefing.com reports. The brokerage set an “outperform” rating and a $5.00 price target on the biopharmaceutical company’s stock. SVB Leerink’s price target would indicate a potential upside of 220.51% from the stock’s previous close.

LXRX has been the subject of several other reports. StockNews.com upgraded Lexicon Pharmaceuticals to a “sell” rating in a research note on Monday, April 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, April 23rd.

Lexicon Pharmaceuticals Trading Down 1.3 %

LXRX stock opened at $1.56 on Tuesday. Lexicon Pharmaceuticals has a 1-year low of $0.92 and a 1-year high of $3.79. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.60 and a quick ratio of 5.58. The company has a market capitalization of $384.13 million, a price-to-earnings ratio of -1.95 and a beta of 1.27. The business has a 50 day simple moving average of $2.17 and a two-hundred day simple moving average of $1.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.68 million. Research analysts anticipate that Lexicon Pharmaceuticals will post -0.71 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Several hedge funds have recently modified their holdings of LXRX. Cantor Fitzgerald L. P. purchased a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $25,000. TIAA Trust National Association purchased a new stake in Lexicon Pharmaceuticals during the 3rd quarter valued at $29,000. Principal Securities Inc. purchased a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at $33,000. Commonwealth Equity Services LLC raised its holdings in Lexicon Pharmaceuticals by 160.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 24,400 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Lexicon Pharmaceuticals by 350.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 22,043 shares during the period. 74.70% of the stock is owned by hedge funds and other institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.